Oslo, Norway - Vistin Pharma ASA (VISTN) announces the financial results for the fourth quarter and preliminary results of 2025.
Solid last quarter of 2025 signs-off a record year for Vistin Pharma with all-time high revenue and EBITDA.
Revenue in the fourth quarter ended at MNOK 111 compared to MNOK 114 in Q4 2024. Record high sales volume in quarter (+9%), offset by lower global metformin prices compared to same quarter last year. 2025 full year revenue ended at all-time high MNOK 452 compared to MNOK 430 last year. Sales volume increased by 12% in 2025.
Fourth quarter EBITDA ended at MNOK 26 compared to MNOK 28 in Q4 2024. EBITDA was positively affected by higher sales volume, offset by product mix compared to same quarter last year. 2025 full year all-time high EBITDA of MNOK 115 compared to MNOK 104 last year, a 10% increase
Earnings per share for 2025 ended at NOK 1,69 compared to 1,42 in 2024, an increase of 19%.
'We are pleased with our 2025 results which shows that we are able to grow our top- and bottom line through strong commercial execution creating healthy earnings for our owners'
Magnus Tolleshaug, CEO
Vistin has a strong balance sheet with equity ratio of 75% and net cash position of MNOK 16 as of year-end.
Based on preliminary 2025 results the Board of Directors will propose for the AGM to pay-out an ordinary cash dividend of up to NOK 1.50 per share, to be paid partly with NOK 1 in May and up to NOK 0.50 in November.
Contact:
Alexander Karlsen
Tel: +47 97 05 36 21
Email: alexander.karlsen@vistin.com
(C) 2026 Electronic News Publishing, source ENP Newswire